TG Therapeutics

Update in progress

TGTX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell–mediated diseases in the U.S. and abroad. It markets BRIUMVI, an anti-CD20 antibody for adults with relapsing forms of multiple sclerosis. Its pipeline includes Ublituximab IV (glycoengineered anti-CD20), TG-1701 (oral BTK inhibitor), and TG-1801 (CD47/CD19 bispecific). Licenses: LFB, GTC, Ildong, Jiangsu Hengrui. Founded 1993, based in Morrisville, NC.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationUnited States
CEOMr. Michael S. Weiss Esq., J.D.
Founded1993
Employees399
Websitewww.tgtherapeutics.com

Identifiers

ISINUS88322Q1085
FIGIBBG000FVZQY1
LEI529900X21UKABN9NJ529
CUSIP048785109
CIK0001001316